source
- Alkermes reports promising Phase 1b results for orexin agonist ALKS 7290 in ADHDAlkermes presented data from a Phase 1b study that evaluated its orexin-based compound ALKS 7290 in adults with attention-deficit/hyperactivity disorder. The trial enrolled 50 participants who rece…
- AI's early, uneven impact on clinical trials sparks surpriseThe pharmaceutical industry is beginning to see artificial intelligence applied to clinical trial processes, though adoption is occurring in fits and starts. Early uses of AI are emerging in areas…